Research summary ·
Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation - a systematic review and meta-analysis with GRADE assessment.
Written based on 1 research study on PubMed, searched on 13 Nov 2026.
What was studied
This review pooled results from earlier trials of a drug called plecanatide. It looked at people with chronic idiopathic constipation, or CIC. It also looked at people with IBS with constipation, called IBS-C. Each trial compared plecanatide with a dummy pill, called a placebo. The team searched for trials up to August 2025. They checked bowel movements and how hard or soft stools were.
What they found
Plecanatide raised the number of full bowel movements at every dose studied. The largest gain in full bowel movements was seen at 9 mg. Bowel movements in general also rose at doses of 1, 3 and 6 mg. Stools, belly pain and bloating got better, mainly at 3 to 6 mg. Doses of 1 mg and 9 mg did better than 0.3 mg. Diarrhea was the most common side effect. It was also the main reason people stopped the drug. Other safety results did not differ in a clear way.
What it means for patients
The authors say plecanatide is mostly well tolerated in CIC and IBS-C. They felt 3 mg balanced benefit and safety more than other doses. They see the drug as a real treatment choice for these conditions. But diarrhea is still a worry, and it rises with the dose.
Why it is not certain yet
The abstract does not say how many trials or people were included. It does not give the follow-up length for the trials. The abstract does not report the quality ratings from its GRADE check. A review can only be as good as the studies in it.
Source
Gut relief revisited: plecanatide in chronic idiopathic constipation and irritable bowel syndrome with constipation - a systematic review and meta-analysis with GRADE assessment.
PubMed · PMID 42934540We restate facts from the source record in our own words. The original wording belongs to its publisher.
This page is not medical advice. Talk to your doctor about your own care.
Back to Irritable bowel syndrome publications